Original Article

Factors Influencing Consumer Purchasing Patterns of Generic Versus Brand Name Over-the-Counter Drugs

Authors: Erol Kohli, MD, MPH, Allison Buller, MS

Abstract

Objectives: US consumers spend more than $20 billion/year on over-the-counter (OTC) drugs. Although generic and brand name OTC drugs share the same active ingredients and undergo the same rigorous Food and Drug Administration approval process, brand name formulations continue to lead the OTC drug market with a higher market share. There is a limited amount of publicly available information regarding consumer perceptions and awareness about generic and brand name OTC drugs. The main objective of this research was to understand what factors influence US consumers to purchase generic versus brand name OTC drugs.


Methods: The researchers used a 20-question, self-administered, multiple-choice survey to collect data on the factors influencing consumers’ preferences for generic versus brand name OTC drugs.


Results: Results revealed that the single most influential factor for participants when purchasing OTC drugs was lower cost.


Conclusions: Although economic factors play an important role in influencing consumers to choose generic formulations, a variety of other factors including advertisements, duration of the OTC effectiveness, severity of sickness, preferable form of OTC medication, safety of the OTC, relief of multiple symptoms, and preferred company will persuade others to pay more for brand name drugs. Ultimately, increased awareness and use of generic OTC drugs may result in substantial cost savings for consumers.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Ganther JM, Kreling DH. Consumer perceptions of risk and required cost savings for generic prescription drugs. J Am Pharm Assoc 2000; 40: 378–383.
 
2. Himmel WA, Simmenroth-Nayda A, Niebling W, et al. What do primary care patients think about generic drugs? Int J Clin Pharmacol Ther 2005; 43: 472–479.
 
3. Hellerstein JK. The importance of the physician in the generic versus trade-name prescription decision. Rand J Econ 1998; 29: 108–136.
 
4. Decollogny A, Eggli Y, Halfon P, et al. Determinants of generic drug substitution in Switzerland. BMC Health Serv Res 2011; 11: 17.
 
5. Shrank WH, Liberman JN, Fischer MA, et al. Physician perceptions about generic drugs. Ann Pharmacother 2011; 45: 31–38.
 
6. Rizzo JA, Zeckhauser R. Generic script share and the price of brand-name drugs: the role of consumer choice. Int J Health Care Finance Econ 2009; 9: 291–316.
 
7. Haas JS, Philips KA, Gerstenberger EP, et al. Potential savings from substituting generic drugs for brand name drugs: medical expenditure panel survey, 1997–2000. Ann Intern Med 2005; 142: 891–897.
 
8. Shrank WH, Cox ER, Fischer MA, et al. Patients’ perceptions of generic medications. Health Aff (Millwood) 2009; 28: 546–556.
 
9. Halme M, Linden K, Kääriä K. Patients’ preferences for generic and branded over-the-counter medicines: an adaptive conjoint analysis approach. Patient 2009; 2: 243–255.